Home ›
Prostate Cancer Trials ›
NCT05191680
TherApeutics in Early ProState Cancer (TAPS02)
This is a phase 2, randomised, multicentre, double-blind, placebo-controlled trial investigating the use of short term androgen deprivation therapy in the form of apalutamide (Erleada) in men on active surveillance for prostate cancer.
Trial Details
NCT ID NCT05191680
Phase PHASE2
Sponsor Cambridge University Hospitals NHS Foundation Trust
Status RECRUITING
Cancer Type Prostate Cancer
Interventions Apalutamide Oral Tablet [Erleada] Placebo
Locations (sample) Cambridge, Cambridgeshire, United Kingdom|52.2,0.11667 Bristol, United Kingdom|51.45523,-2.59665 Bury St Edmunds, United Kingdom|52.2463,0.71111 Dartford, United Kingdom|51.44657,0.21423 London, United Kingdom|51.50853,-0.12574
Key Eligibility Criteria
To be included in the trial the patient must: Have given written informed consent to participate. Be aged 18 or over. Have an Eastern Cooperative Oncology Group (ECOG) status 0-2.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Prostate Cancer Trials on Trialify →